Key Insights

Highlights

Success Rate

92% trial completion (above average)

Published Results

11 trials with published results (7%)

Research Maturity

61 completed trials (40% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

3.3%

5 terminated out of 153 trials

Success Rate

92.4%

+5.9% vs benchmark

Late-Stage Pipeline

5%

7 trials in Phase 3/4

Results Transparency

18%

11 of 61 completed with results

Key Signals

11 with results92% success

Data Visualizations

Phase Distribution

82Total
Not Applicable (47)
Early P 1 (3)
P 1 (12)
P 2 (13)
P 3 (4)
P 4 (3)

Trial Status

Completed61
Recruiting36
Unknown25
Not Yet Recruiting10
Active Not Recruiting8
Terminated5

Trial Success Rate

92.4%

Benchmark: 86.5%

Based on 61 completed trials

Clinical Trials (153)

Showing 20 of 20 trials
NCT05741853Not ApplicableRecruiting

Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia

NCT05508789Phase 3Active Not Recruiting

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

NCT06122662Phase 2Completed

AMX0035 and Progressive Supranuclear Palsy

NCT06088121Not ApplicableRecruiting

Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia

NCT07545473Not ApplicableRecruiting

Retinal Hyperspectral Imaging in Neurodegenerative Diseases

NCT06672237Phase 3Recruiting

A Phase 3 Study of NTLA-2001 in ATTRv-PN

NCT07514520Active Not Recruiting

Decision-making, Ethical Consent, and Interactive Dialogue in Ongoing Neurocognitive Decline - DECISION

NCT05318976Phase 2Completed

A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

NCT07489898Not Yet RecruitingPrimary

Novel Technologies to Measure Vision-related Quality of Life

NCT05354622Recruiting

Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)

NCT04838301Phase 2Recruiting

Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease

NCT07470710Early Phase 1Not Yet RecruitingPrimary

Study on the Application of ¹⁸F-FCOB04, a MAO-B Targeted PET Imaging Agent, in Neurodegenerative Diseases

NCT06579209Not ApplicableCompleted

NAD+ Oral Supplement Pilot Intervention in Adult Females

NCT05522387Phase 2Terminated

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

NCT07396818Phase 1Not Yet Recruiting

Kamlanoflast In Amyotrophic Lateral Sclerosis

NCT06111014Phase 3TerminatedPrimary

Continuation Study for Latozinemab

NCT07324330Not ApplicableRecruiting

Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity

NCT06643858Enrolling By Invitation

Normal Chinese Lifespan Brain Charts Initiative (NCLBCI)

NCT07268079Recruiting

Validation of the VIRADIA App for Neurological and Cognitive Diagnostics in Virtual Reality

NCT05095870Completed

Evaluation of the Peripheral Nerve Ultrasound as a Diagnostic Tool in CANVAS Neuropathies

Scroll to load more

Research Network

Activity Timeline